Team

  • Didier Hoch is a director of a publicly traded company, OSE Immunotherapeutics, and was previously a director of DBV Technologies and Genticel. He was from 2011 to 2013 Chairman of Pevion Biotech and from 2013 to 2018 of the Biovision Forum and the startup gas pedal “Big Booster”. Didier Hoch was from 2000 to 2010, President of Sanofi-Pasteur- MSD, a joint venture dedicated to vaccines between Sanofi & Merck. Didier Hoch also held various managerial positions at Rhône Poulenc Rorer, then Aventis (“VP Middle East -Africa”). Former president of the association of vaccine manufacturers “Vaccine Europe” and president of the Biotechnology Committee of LEEM.

  • Thibaut du Fayet brings to the company over 20 years of experience in the pharmaceutical and life sciences industry. After obtaining an MBA from Essec Business School in 1992, he became Senior Managing Director for 6 years at Bossard-Gemini. Since 2000, he has held management positions, first at Rhône Poulenc as Director of Strategy for four years and then at BioMerieux, where he was also Marketing and Strategy Director for four years. In 2008, he joined Transgene where he spent 13 years as Vice President of Partnership Development, Alliances and Program Management.

  • Cindy is a microbiologist, expert in bacteriology. She obtained a PhD at the Pasteur Institute (Paris) in the antibiotic resistance, virulence and genetic diversity of Klebsiella. She has also worked on other major pathogens in human clinical practice, such as listeria and staphylococcus aureus.

    Prior to joining Pherecydes Pharma, Cindy developed new phage display methods and acquired substantial knowledge of bacteriophage biology and genomics. Her international experience (UMC Utrecht, Netherlands) has led her to manage R&D collaborations with industrial potential.

  • Frédérique, Doctor in Pharmacy and Engineer in Biotechnology, is a graduate of the Universities Blaise Pascal Clermont II, Montpellier I and Polytech Clermont-Ferrand. She has some twenty years of experience mainly as Quality Director in large pharmaceutical groups such as MSD, Europhartech, Carbogen Amcis and 4D Pharma PLC. She is the founder of 5QBD, a firm specialized in Quality and Business Development for biotech companies.

  • Dr. Pascal Birman has 30 years of experience in medical research and pharmaceutical development, particularly in endocrinology and metabolic diseases. After a career as a physician at the AP-HP (1981-1990), he joined the Servier Group as Head of International Projects, and then held the executive positions of Director of Therapeutic Research and Clinical Operations Director for Europe and Asia. In 2004, Dr. Birman joined the pharmaceutical company Ipsen where he worked for 13 years in several key positions until becoming Vice President of Global Clinical Development Programs.

  • Céline Breda began her career at Sanofi Pasteur in France and the United States. In 2005, she joined the biotech company Valneva, where she headed up pharmaceutical operations for over eight years. Following the sale of Valneva’s bioproduction site in Nantes in 2013, she took over the Operations Management of this unit, initially for the company BE Vaccines, a subsidiary of the Indian pharmaceutical group Biological E, and then, from 2019, for the company Naobios, a subsidiary of CDMO Clean Biologics.

Supervisory Board

Members

  • Didier Hoch
    Chairman - Independent
  • Maryvonne Hiance
    Vice-Chairwoman - Independente
  • Franck Lescure
    Permanent representative of Elaia Partners
  • Leila Nicolas
    Permanent representative of Go Capital
  • Guy Rigaud
    Member
  • Robert Sebbag
    Member
  • Eric Leire
    Member

Know more about our partnerships